Loading stock data…
ADXN
$7.00+0.07 (+1.08%)
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Addex Therapeutics Ltd in the Healthcare sector is trading at $6.90. The stock is currently 43% below its 52-week high of $12.05, remaining 13.4% below its 200-day moving average. Technical signals show neutral RSI of 54 and bullish MACD crossover, explaining why ADXN maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$7.00
Potential Upside
5%
Whystock Fair Value$7.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs includ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$8.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-102.32%
Volume
Today's trading volume
1,239
Recent News
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ...
Despite stable financials, Addex Therapeutics Ltd (ADXN) focuses on promising R&D progress and strategic partnerships to drive future growth.
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
Despite a decrease in income and rising liabilities, Addex Therapeutics Ltd (ADXN) makes significant strides in drug development and strategic partnerships.
European Market Insights: Addex Therapeutics Among 3 Promising Penny Stocks
The European stock market has shown resilience, with the pan-European STOXX Europe 600 Index rising amid expectations of a potential rate cut by the U.S. Federal Reserve. As investors navigate these shifting economic landscapes, penny stocks emerge as an intriguing area of focus, offering opportunities in smaller or newer companies at lower price points. Despite being considered a throwback term, penny stocks can still represent valuable investment prospects when backed by strong financials...